Publications by authors named "Nilo B Cater"

Claim this Profile
H
Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Ambarish Pandey, Ahmed A Kolkailah, Darren K McGuire, Robert C Frederich, Nilo B Cater

Eur J Heart Fail· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
Francesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, Christopher P Cannon, David Z I Cherney, Nilo B Cater

Diabetes Obes Metab· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial.
David Z I Cherney, Robert Frederich, Richard E Pratley, Francesco Cosentino, Samuel Dagogo-Jack, Nilo B Cater

Kidney Dis (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
Vikas S Sridhar, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard E Pratley, Nilo B Cater

Diabetes Obes Metab· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table.
François Mach, Frank L J Visseren, Nilo B Cater, Nejoua Salhi, Jarkko Soronen

J Clin Lipidol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino, Christopher P Cannon, Robert C Frederich, Nilo B Cater

Eur Heart J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Brian S Wojeck, Silvio E Inzucchi, Ian J Neeland, James P Mancuso, Robert Frederich, Nilo B Cater

Sleep Breath· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack, David Z I Cherney, Francesco Cosentino, Nilo B Cater

Diabetes Obes Metab· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Karen D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, David Z I Cherney, Francesco Cosentino, Nilo B Cater

Diabetes Obes Metab· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.
Linong Ji, Jie Liu, Zhi Jin Xu, Zhiqi Wei, Ruya Zhang, Nilo B Cater

Diabetes Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Matthew W Segar, Ahmed A Kolkailah, Robert Frederich, Annpey Pong, Christopher P Cannon, Nilo B Cater

Diabetes Obes Metab· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
Francesco Cosentino, Christopher P Cannon, Robert Frederich, David Z I Cherney, Samuel Dagogo-Jack, Nilo B Cater

Circulation· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, Urszula Masiukiewicz, Richard Pratley, Nilo B Cater

Circulation· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Jie Liu, Shrita Patel, Nilo B Cater, Larry Wu, Susan Huyck

Diabetes Obes Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
Michael D Ezekowitz, Charles V Pollack, Jonathan L Halperin, Richard D England, Sandra VanPelt Nguyen, Nilo B Cater

Eur Heart J· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
Terje R Pedersen, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders G Olsson

Am J Cardiol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Matti J Tikkanen, Michael Szarek, Rana Fayyad, Ingar Holme, Nilo B Cater

J Am Coll Cardiol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Ingar Holme, Michael Szarek, Nilo B Cater, Ole Faergeman, John J P Kastelein

Eur J Cardiovasc Prev Rehabil· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Ingar Holme, Nilo B Cater, Ole Faergeman, John J P Kastelein, Anders G Olsson

Ann Med· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Matti J Tikkanen, Ingar Holme, Nilo B Cater, Michael Szarek, Ole Faergeman

Am J Cardiol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
John J P Kastelein, Wim A van der Steeg, Ingar Holme, Michael Gaffney, Nilo B Cater

Circulation· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responsiveness of plasma lipids and lipoproteins to plant stanol esters.
Nilo B Cater, Ana-Barbara Garcia-Garcia, Gloria Lena Vega, Scott M Grundy

Am J Cardiol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Gloria Lena Vega, Nilo B Cater, Shinishi Meguro, Scott M Grundy

Am J Cardiol· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Gloria Lena Vega, Nilo B Cater, Dariusch R Hadizadeh, Shinichi Meguro, Scott M Grundy

Clin Pharmacol Ther· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Gloria Lena Vega, Patrick T S Ma, Nilo B Cater, Neil Filipchuk, Shinichi Meguro

Am J Cardiol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis